Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Oct 1, 2015 05:56PM Form 4 Sientra, Inc. For: Sep 29 Filed by: ORBIMED ADVISORS LLC
Sep 29, 2015 05:25PM U.S. biotech bloodbath hits hedge funds but some bargains emerge
Sep 21, 2015 03:39PM Biotech stocks sink after Hillary Clinton 'price gouging' tweet
Sep 8, 2015 07:00AM ContraFect Appoints Key Business Executives
Sep 4, 2015 04:36PM Form SC 13G/A Biotie Therapies Corp. Filed by: ORBIMED ADVISORS LLC
Aug 17, 2015 04:41PM Form SC 13D/A Affimed N.V. Filed by: ORBIMED ADVISORS LLC
Aug 14, 2015 04:24PM Form 13F-HR ORBIMED ADVISORS LLC For: Jun 30
Aug 12, 2015 04:07PM Xtant Medical Reports First Half 2015 Financial Results
Aug 12, 2015 04:07PM Xtant Medical Reports First Half 2015 Financial Results
Aug 6, 2015 09:00AM Avitide, Inc., Secures Series C Financing to Expand On-demand Biopharmaceutical Affinity Purification Platform and Achieve Profitability
Jul 9, 2015 04:24PM Form SC 13D PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jul 8, 2015 08:00AM Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Jul 2, 2015 04:43PM Form SC 13G Cynapsus Therapeutics Filed by: ORBIMED ADVISORS LLC
Jun 26, 2015 04:58PM Form SC 13G Biotie Therapies Corp. Filed by: ORBIMED ADVISORS LLC
Jun 23, 2015 09:32AM Clementia Pharmaceuticals Raises U.S. $60 Million in Mezzanine Financing to Support Development of Palovarotene for Fibrodysplasia Ossificans Progressiva
Jun 22, 2015 02:10AM Aerocrine Repays Loan Due to Change in Control
Jun 17, 2015 08:00AM Cleave Biosciences to Present at JMP Securities Life Sciences Conference 2015
Jun 4, 2015 03:03PM New Inspire Upper Airway Stimulation Therapy 18-Month Durability Research Shows Sustained Reductions in Obstructive Sleep Apnea (OSA) Severity, Improvement in Quality of Life
May 20, 2015 05:16PM Form SC 13D/A Relypsa Inc Filed by: ORBIMED ADVISORS LLC
May 15, 2015 04:36PM Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
May 15, 2015 02:41PM Form SC 13D Adaptimmune Therapeutics Filed by: ORBIMED ADVISORS LLC
May 14, 2015 01:03PM Form SC 13D/A Affimed N.V. Filed by: ORBIMED ADVISORS LLC
Apr 22, 2015 11:46AM Inspire Therapy Approved for Sleep Apnea Patients at Military and VA Hospitals
Apr 20, 2015 12:00PM Study of Upper Airway Stimulation (UAS) Therapy for Sleep Apnea Named a Top Ten Outstanding Research Paper
Apr 6, 2015 06:00AM Natera, Inc., Non-Invasive Genetic Testing Leader, Secures $55 Million in Private Financing
Mar 30, 2015 04:10PM Form SC 13D/A INTERCEPT PHARMACEUTICAL Filed by: ORBIMED ADVISORS LLC
Mar 25, 2015 05:05PM Pieris Pharmaceuticals Reports Full-Year 2014 Financial Results and Provides Corporate Update
Mar 25, 2015 04:51PM Form SC 13D/A INTERCEPT PHARMACEUTICAL Filed by: ORBIMED ADVISORS LLC
Mar 9, 2015 04:26PM Form SC 13G SYNERGY PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Mar 6, 2015 05:06PM Form SC 13D/A Relypsa Inc Filed by: ORBIMED ADVISORS LLC
Feb 20, 2015 01:45PM Form SC 13D/A Affimed N.V. Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 04:18PM Form SC 13G/A ACCELERON PHARMA INC Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 04:17PM Form SC 13G/A XENOPORT INC Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 04:14PM Form SC 13G/A UROPLASTY INC Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 04:12PM Form SC 13G/A PERNIX THERAPEUTICS HOLD Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 04:11PM Form SC 13G/A Prothena Corp plc Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 04:09PM Form SC 13G/A INSULET CORP Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 04:07PM Form SC 13G/A ORASURE TECHNOLOGIES Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 04:06PM Form SC 13G/A InspireMD, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 04:02PM Form SC 13G/A Mirati Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 03:58PM Form SC 13G Sientra, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 03:45PM Form SC 13G Tornier N.V. Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 03:45PM Form SC 13G/A MEI Pharma, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 03:42PM Form SC 13G SINOVAC BIOTECH LTD Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 03:40PM Form SC 13G ProQR Therapeutics N.V. Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 03:40PM Form SC 13G/A IMPAX LABORATORIES INC Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 03:39PM Form SC 13G/A INFINITY PHARMACEUTICALS Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 03:38PM Form SC 13G NEUROCRINE BIOSCIENCES Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 03:37PM Form SC 13G/A FLUIDIGM CORP Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 03:36PM Form SC 13G MOLINA HEALTHCARE INC Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed